Cost-Effectiveness of Inclisilan Injection in Patients with Atherosclerotic Cardiovascular Disease
10.3870/j.issn.1004-0781.2025.03.022
- VernacularTitle:英克司兰注射液治疗动脉粥样硬化性心脏病成本效果分析
- Author:
Bing FENG
1
;
Ning GAO
;
Shengnan GAO
;
Mengna NIU
;
Shan GUO
;
Guoqiang LIU
Author Information
1. 河北医科大学第三医院临床药学部,石家庄 050051
- Publication Type:Journal Article
- Keywords:
Inclisiran injection;
Atherosclerosis;
Pharmacoeconomics;
Cardiovascular disease;
Health technology assess-ment
- From:
Herald of Medicine
2025;44(3):466-472
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cost-effectiveness of inclisiran injection treatment in patients with atherosclerotic heart disease(ASCVD)in China.Methods From the perspective of China's health system,according to the Markov model,patients with ASCVD were divided into inclisilan injection group and placebo group,and both groups were treated with convention-al lipid-lowering drugs.The study period was 25 years.The rate parameters,cost parameters,and effectiveness parameters were de-rived from the ORION-18 trial and other literature.Effects were expressed as quality-adjusted life-years(QALYs).The incremental cost-effectiveness ratio(ICER)was used to evaluate the economy of inclisilan injection.One-way sensitivity analysis and probabil-ity sensitivity analysis were used to verify the reliability of the results.Results The treatment effect of the inclisilan injection group was higher(10.02 QALYs),and the cost of the placebo group was lower(255 179 yuan).The ICER of the two groups was 137 850 yuan per QALY gained,and using 257 094 yuan per capita by 2022 as the threshold,the treatment would be economically advantageous.Sensitivity analysis supported this result.Conclusion At present,the additional use of inclisilan injection can get a better treatment effect,and it has economic advantages under the threshold of three times GDP per capita in China.
